NCT04628936View on ClinicalTrials.gov

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

March 10, 2023

Study Completion Date

June 12, 2023

Conditions
PolymyositisDermatomyositis
Interventions
DRUG

KZR-616

Subcutaneous 30 mg for 1 week, then 45 mg weekly

Trial Locations (10)

15213

KZR Research Site, Pittsburgh

16635

KZR Research Site, Duncansville

21224

KZR Research Site, Baltimore

33136

KZR Research Site, Miami

48109

KZR Research Site, Ann Arbor

66160

KZR Research Site, Kansas City

78756

KZR Research Site, Austin

90211

KZR Research Site, Beverly Hills

92868

KZR Research Site, Orange

Unknown

KZR Research Site, Prague

Sponsors
All Listed Sponsors
lead

Kezar Life Sciences, Inc.

INDUSTRY

NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. | Biotech Hunter | Biotech Hunter